Voyager Therapeutics (NASDAQ:VYGR) Earns Outperform Rating from Analysts at Wedbush

Stock analysts at Wedbush initiated coverage on shares of Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) in a research note issued on Friday, Marketbeat Ratings reports. The firm set an "outperform" rating and a $11.00 price target on the stock. Wedbush's price objective points to a potential upside of 60.35% from the stock's previous close.

Other equities analysts have also recently issued research reports about the stock. StockNews.com upgraded shares of Voyager Therapeutics from a "hold" rating to a "buy" rating in a research report on Monday, November 18th. Canaccord Genuity Group restated a "buy" rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partnrs raised Voyager Therapeutics to a "strong-buy" rating in a research note on Wednesday, October 16th. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Finally, Leerink Partners assumed coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an "outperform" rating and a $15.00 price objective on the stock. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Voyager Therapeutics presently has an average rating of "Buy" and an average price target of $17.50.

Voyager Therapeutics Stock Up 18.7 %

Shares of NASDAQ VYGR traded up $1.08 during midday trading on Friday, hitting $6.86. The company had a trading volume of 1,190,212 shares, compared to its average volume of 532,081. The firm has a market capitalization of $374.76 million, a price-to-earnings ratio of 9.66 and a beta of 0.89. Voyager Therapeutics has a twelve month low of $5.19 and a twelve month high of $11.72. The business has a 50-day simple moving average of $6.51 and a two-hundred day simple moving average of $7.31.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.29. The company had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period last year, the firm earned ($0.59) EPS. On average, equities analysts forecast that Voyager Therapeutics will post -1.03 EPS for the current year.

Insider Activity at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm's stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now directly owns 86,001 shares of the company's stock, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.53% of the company's stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of large investors have recently bought and sold shares of the stock. Victory Capital Management Inc. grew its holdings in shares of Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company's stock worth $102,000 after purchasing an additional 1,630 shares during the period. SummerHaven Investment Management LLC lifted its position in Voyager Therapeutics by 2.5% during the second quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company's stock valued at $611,000 after buying an additional 1,921 shares in the last quarter. Hunter Perkins Capital Management LLC grew its stake in Voyager Therapeutics by 3.3% during the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company's stock worth $375,000 after buying an additional 2,025 shares during the period. Empowered Funds LLC increased its position in shares of Voyager Therapeutics by 5.4% in the third quarter. Empowered Funds LLC now owns 44,809 shares of the company's stock worth $262,000 after acquiring an additional 2,278 shares in the last quarter. Finally, Federated Hermes Inc. raised its stake in shares of Voyager Therapeutics by 0.5% in the 2nd quarter. Federated Hermes Inc. now owns 554,214 shares of the company's stock valued at $4,384,000 after acquiring an additional 2,638 shares during the period. Hedge funds and other institutional investors own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.